ABCB6 antibody
- Known as:
- ABCB6 (anti-)
- Catalog number:
- orb10022
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- ABCB6 antibody
Related genes to: ABCB6 antibody
- Gene:
- ABCB6 NIH gene
- Name:
- ATP binding cassette subfamily B member 6 (Langereis blood group)
- Previous symbol:
- -
- Synonyms:
- EST45597, umat, MTABC3
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 1999-10-26
- Date modifiied:
- 2019-04-23
Related products to: ABCB6 antibody
Related articles to: ABCB6 antibody
- Osteosarcoma (OS) is a malignant bone tumor that predominantly affects adolescents. Due to its early metastatic tendency and chemoresistance, long-term survival rates in patients have not shown significant improvement over time, highlighting the urgent need for novel molecular targets and therapeutic strategies. Ferroptosis, a form of programmed cell death driven by iron-dependent lipid peroxidation, offers a promising avenue for overcoming drug-resistant tumors. ATP-binding cassette subfamily B member 6 () belongs to the ATP-binding cassette (ABC) transporter superfamily and is mainly localised to the outer mitochondrial membrane, where it participates in haem synthesis and intracellular iron transport. Recent studies have indicated that is aberrantly expressed in various malignancies and regulates tumor progression, yet its role and mechanism in OS remain unexplored. The present study aims to systematically characterise the expression pattern, clinical prognostic significance, and biological functions of in OS, and to dissect the molecular mechanism by which governs ferroptosis in OS cells, thereby providing a theoretical foundation for -targeted therapy. - Source: PubMed
Lin ZiliLuo HaoLi XiangyaoLuo Wei - Familial pseudohyperkalemia (FP) is an asymptomatic condition characterized by an increased rate of potassium leak from red blood cells (RBC) on refrigeration. The effect of washing on FP RBC was investigated. - Source: PubMed
Publication date: 2026/07/29
Meli AthinoulaStevens-Hernandez Christian JMohamudally AzharSakharkar KalpitaNew Helen VCardigan RebeccaBruce Lesley J - The Lan antigen is a high-prevalence red blood cell antigen encoded by the ATP binding cassette subfamily B member 6 (ABCB6) gene. Variants in this gene are responsible for Lan null and variant phenotypes. Individuals lacking the Lan antigen may develop anti-Lan antibodies following sensitizing events such as transfusion or pregnancy. Hemolytic disease of the fetus and newborn (HDFN) caused by anti-Lan antibodies is extremely rare. - Source: PubMed
Publication date: 2026/07/10
Feng JingTian LiZhang YanZhu KaiWang HaijuanZhao HongYe LuyiChen Jian - Multidrug resistance (MDR) remains a major obstacle in the clinical treatment of leukemia, severely limiting therapeutic efficacy and leading to poor patient outcomes. Drug efflux mediated by ATP-binding cassette (ABC) transporters represents a central mechanism driving cancer MDR. In this study, we identified ABCB6 as a critical mediator of MDR in leukemia through its role in promoting drug efflux. Using membrane-focused liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) analysis of the leukemia cell line K562 and its MDR derivative K562/A02, we screened for differentially expressed transporters and identified ABCB6 as a candidate molecule. We further confirmed that ABCB6 is abundantly expressed on the plasma membrane of K562/A02 cells. Functional analyses demonstrated that altered ABCB6 expression did not significantly affect cell proliferation or apoptosis; however, targeted knockdown of ABCB6 markedly restored the sensitivity of K562/A02 cells to adriamycin (ADR) and cytosine arabinoside (Ara-C). Mechanistic studies revealed that ABCB6 contributes to ADR efflux from leukemia cells, thereby reducing intracellular drug accumulation and weakening its cytotoxic activity. Together, these findings establish ABCB6 as a previously unrecognized efflux transporter that contributes to MDR in leukemia and highlight ABCB6 as a potential therapeutic target for overcoming MDR. - Source: PubMed
Publication date: 2026/06/02
Jiao ZhongxiangYu HuasongZhang YiranYang MingZhang WenshanZhang HexiaoWang WeiZhang MingheLi XiaoyueLi YinghuiGao Yingdai - Combination therapies are critical for enhancing and prolonging the efficacy of EGFR inhibitors. Here, we uncover FUNDC1-dependent mitophagy as a key protective mechanism in EGFR-mutant non-small cell lung cancer (NSCLC). We discover that nitidine, a bioactive component of the traditional Xihuang Pill formulation, synergises with the EGFR inhibitor osimertinib. Mechanistically, nitidine and osimertinib synergistically disrupt FUNDC1-mediated mitophagy, leading to mitochondrial dysfunction and accumulation of reactive oxygen species in EGFR-mutant NSCLC. We further show that both osimertinib and nitidine decrease HIF-1α protein levels, thereby downregulating FUNDC1 expression. Nitidine-induced downregulation of HIF-1α and FUNDC1 depends on the mitochondrial transporter ABCB6. Notably, acquired resistance to osimertinib exhibits adaptive downregulation of FUNDC1, rendering resistant EGFR-mutant NSCLC cells more sensitive to nitidine. Collectively, these findings position nitidine as a promising therapeutic strategy to enhance the efficacy of EGFR inhibitors and overcome osimertinib resistance in EGFR-mutant NSCLC. - Source: PubMed
Xu FanWang XiaoshanLi MinLi YiLi XiaojuanYan QingqingKong FanmingHuang QihongCao XinXue Ying